Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
Abstract No : 9518
Abstract Type : Poster Discussion Session
Indication : ALK+ NSCLC
Intervention : Alectinib (ALC) versus crizotinib (CRZ)
Company : F. Hoffman-La Roche Ltd
Technology : Small molecule
Results:
This is the first global randomized study of a 2nd generation ALK TKI to demonstrate a clinically meaningful improvement in OS vs CRZ in ALK+ NSCLC (5-year survival rate: 62.5%, ALC vs 45.5%, CRZ); longer FU is required as OS data remain immature.
Conclusion:
Around 62.5% patients are still alive at 5 years on alectinib compared to 45.5% in first crizotinib (CRZ) in the global randomized study which will further strengthen the position of first line usage of alectinib
Commentary:
Roche presented long term data of alectinib from ALEX study in frontline advanced ALK+ NSCLC.
Refer to ALK positive NSCLC Market report for detailed Insights.
